Want to see IN:TATVA full AI Analyst Report?
Top Page
Tatva Chintan Pharma Chem Limited
(TATVA)
Select Model
Select Model
Rating:48Neutral
Price Target:
₹1,643.00
▲(18.34% Upside)
Action:Reiterated
Date:10/23/26
Overall score is held back primarily by weak cash-flow quality (persistently negative free cash flow) and a premium valuation (high P/E with minimal dividend support). A relatively strong balance sheet provides some stability, but technical indicators and price vs key moving averages suggest limited near-term momentum.
Positive Factors
Revenue Recovery
The FY2026 revenue rebound indicates renewed demand across the company’s specialty-chemical portfolio after a period of contraction. If maintained, improving sales can support better capacity utilization, strengthen customer relationships, and provide a foundation for earnings recovery over the next several quarters.
Negative Factors
Persistently Negative Free Cash Flow
Negative free cash flow across most periods means reported earnings have not consistently translated into cash available after investment. Continued cash shortfalls can increase reliance on the balance sheet to fund expansion, constrain capital allocation, and make the recovery less durable until conversion improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The FY2026 revenue rebound indicates renewed demand across the company’s specialty-chemical portfolio after a period of contraction. If maintained, improving sales can support better capacity utilization, strengthen customer relationships, and provide a foundation for earnings recovery over the next several quarters.
Read all positive factors
Tatva Chintan Pharma Chem Limited (TATVA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹37.72B
Dividend Yield0.12%
Average Volume (3M)7.05K
Price to Earnings (P/E)60.0
Beta (1Y)1.18
Revenue Growth49.69%
EPS Growth254.75%
CountryIN
Employees793
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)26.90
Shares Outstanding23,392,056
10 Day Avg. Volume9,813
30 Day Avg. Volume7,050
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.15
Price to Sales (P/S)4.87
P/FCF Ratio-29.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.25
Revenue Forecast (FY)₹6.77B
Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model
Company Description
Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for ...
How the Company Makes Money
Tatva Chintan Pharma Chem Limited primarily makes money by manufacturing and selling specialty chemicals—mainly SDPTCs and QAS (including bromide-based and other quaternary ammonium salts), along with specialty chemicals and electrolyte salts—to c...
Tatva Chintan Pharma Chem Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
77
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.50B | 5.06B | 3.83B | 3.43B | 4.24B | 4.34B |
| Gross Profit | 2.75B | 1.82B | 619.74M | 1.60B | 1.91B | 2.32B |
| EBITDA | 1.29B | 967.07M | -875.86M | 693.88M | 680.24M | 1.09B |
| Net Income | 629.18M | 420.54M | 57.13M | 303.54M | 454.87M | 958.74M |
Balance Sheet | ||||||
| Total Assets | 11.19B | 10.04B | 8.36B | 8.19B | 7.60B | 6.58B |
| Cash, Cash Equivalents and Short-Term Investments | 152.05M | 87.91M | 117.01M | 456.68M | 412.16M | 638.19M |
| Total Debt | 1.70B | 1.20B | 363.88M | 142.71M | 1.70B | 1.20B |
| Total Liabilities | 3.04B | 2.22B | 974.25M | 816.36M | 2.44B | 1.85B |
| Stockholders Equity | 8.15B | 7.82B | 7.39B | 7.37B | 5.15B | 4.73B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -841.44M | -516.01M | -304.71M | -1.75B | -687.79M |
| Operating Cash Flow | 0.00 | 296.30M | 246.71M | 980.44M | 277.83M | 203.78M |
| Investing Cash Flow | 0.00 | -1.17B | -652.54M | -1.21B | -1.01B | -1.97B |
| Financing Cash Flow | 0.00 | 816.19M | 165.66M | 305.19M | 377.95M | 2.35B |
Tatva Chintan Pharma Chem Limited Technical Analysis
Neutral
1388.35
Price Trends
1718.99
Negative
1575.60
Positive
1398.40
Positive
Market Momentum
-27.92
Positive
40.38
Neutral
12.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Neutral. The current price of 1388.35 is below the 20-day moving average (MA) of 1800.59, below the 50-day MA of 1718.99, and below the 200-day MA of 1398.40, indicating a neutral trend. The MACD of -27.92 indicates Positive momentum. The RSI at 40.38 is Neutral, neither overbought nor oversold. The STOCH value of 12.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:TATVA.
Tatva Chintan Pharma Chem Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹107.70B | 24.01 | ― | 0.82% | 5.09% | 5.44% | |
69 Neutral | ₹84.68B | 37.56 | ― | 0.60% | 5.11% | 20.64% | |
60 Neutral | ₹22.57B | 14.78 | ― | 0.12% | 19.76% | 11.74% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹90.46B | 25.57 | ― | 0.88% | 15.41% | 21.76% | |
48 Neutral | ₹37.72B | 60.03 | ― | 0.12% | 49.69% | 254.75% | |
47 Neutral | ₹160.40B | 30.17 | ― | 0.20% | 27.05% | 123.98% |
* General Sector Average
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,612.30
257.43
19.00%
IN:AARTIIND
AARTI Industries Ltd
442.20
60.26
15.78%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,655.50
-216.94
-11.59%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
567.95
-124.64
-18.00%
IN:ROSSARI
Rossari Biotech Ltd
407.45
-234.73
-36.55%
IN:VINATIORGA
Vinati Organics Limited
1,038.90
-649.65
-38.47%
Tatva Chintan Pharma Chem Limited Corporate Events
Tatva Chintan Corrects Key Ratios in Updated Investor Presentation
Oct 19, 2026
Tatva Chintan Pharma Chem Limited operates in the specialty chemicals and pharmaceutical intermediates sector, supplying advanced chemical formulations to domestic and international markets. Listed on both BSE and NSE under the scrip code 543321 a...
Tatva Chintan Plans Analyst Meeting With Motilal Oswal
Oct 16, 2026
Tatva Chintan Pharma Chem Limited has announced that it will participate in a one-to-one virtual meeting with Motilal Oswal Investment Advisors Limited on 26 October 2026, as part of its regular interactions with analysts, financial institutions a...
Tatva Chintan Schedules Earnings Call for Q2 and H1 FY27 Results
Oct 13, 2026
Tatva Chintan Pharma Chem Limited has scheduled an earnings conference call to discuss its financial results for the quarter and half year ended 30 September 2026. The call, hosted by ICICI Securities and featuring Managing Director Chintan Shah a...
Crisil Upgrades Tatva Chintan’s Credit Ratings on Rs.245 Crore Bank Facilities
Sep 8, 2026
Tatva Chintan Pharma Chem Limited has received an upgrade in its credit profile from Crisil Ratings, which raised the company’s long-term rating to Crisil A-/Stable from Crisil BBB+/Stable and its short-term rating to Crisil A2+ from Crisil ...
Tatva Chintan Schedules Virtual Investor Meeting with Ventura Securities on July 30
Jul 24, 2026
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one meeting with Ventura Securities Limited on 30 July 2026 as part of its ongoing engagement with analysts, financial institutions, and investors. The company emphasized that only p...
Tatva Chintan Plans Investor Meeting with Motilal Oswal AMC
Jul 24, 2026
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-to-one meeting with Motilal Oswal Asset Management Company on July 31, 2026, aimed at engaging analysts, financial institutions and investors. The company emphasized that discussions wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.